trending Market Intelligence /marketintelligence/en/news-insights/trending/6rD1WAvtOEmOLbSppbySJA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Molecular Templates completes reverse merger with Threshold Pharmaceuticals

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Molecular Templates completes reverse merger with Threshold Pharmaceuticals

Molecular Templates Inc. completed an all-stock reverse merger with Threshold Pharmaceuticals Inc. and raised $40 million in equity financing from a number of U.S.-based venture capital firms.

Takeda Pharmaceutical Co. Ltd. invested a further $20 million in the combined entity, which will continue under the Molecular Templates name and will be listed on the Nasdaq Capital Market under the MTEM ticker.

Threshold shareholders were expected to own about 34.4% of the combined company, with Molecular Templates shareholders owning the rest. The entity has about $75 million in cash balance, for use in funding research and development activities.

Molecular Templates chief scientific officer and CEO Eric Poma will head the new company by retaining the same positions within the entity. Jason Kim, Molecular Templates' president and CFO, became the president, principal financial officer and COO of the new company.

Threshold's interim CEO, Wilfred Jaeger; senior vice president of finance, Joel Fernandes; and chief medical officer, Tillman Pearce, have resigned.

Takeda Pharmaceuticals nominated Michael Broxson, its vice president and head of R&D business development, to the new company's board, joined by Scott Morenstein, Kevin Lalande and David Hoffmann, who were nominated by the venture capital firms that invested in the entity.

Poma is also a part of the new company's board.

Threshold's former CEO Harold Selick, was appointed the combined company's chairman.

Molecular Templates is developing therapies for oncology.